Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma.

IF 2.2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Esophagus Pub Date : 2024-10-01 Epub Date: 2024-09-02 DOI:10.1007/s10388-024-01085-5

Kazuhiro Shiraishi, Yuki Takeyasu, Shun Yamamoto, Kotoe Oshima, Hiroshi Imazeki, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Atsuo Takasima, Ken Kato

{"title":"Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma.","authors":"Kazuhiro Shiraishi, Yuki Takeyasu, Shun Yamamoto, Kotoe Oshima, Hiroshi Imazeki, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Atsuo Takasima, Ken Kato","doi":"10.1007/s10388-024-01085-5","DOIUrl":null,"url":null,"abstract":"Background: Programmed cell death-1 (PD-1) blockade improves survival in patients with advanced esophageal squamous cell carcinoma (ESCC). However, the efficacy of taxanes after exposure to PD-1 blockade remains unclear in patients with advanced ESCC.Methods: We retrospectively analyzed the clinical outcomes of advanced ESCC patients treated with taxanes (paclitaxel or docetaxel) with/without prior exposure to PD-1 blockade (Exposed /Naïve group) at National Cancer Center Hospital from June 2016 to December 2020.Results: Ninety-nine patients (Exposed group, n = 32; Naïve group, n = 67) were included. The objective response rate (ORR) of the Exposed group was significantly higher than that of the Naïve group (37.5% vs. 13.4%, p = 0.009). The median progression-free survival was similar between the Exposed and Naïve groups (3.8 vs. 2.8 months, HR 1.12, 95% CI 0.65-1.86, p = 0.66). PD-1 blockade exposure independently predicated higher ORR to taxanes in multivariate analysis. Grade ≥ 3 adverse events were comparable between the Exposed and Naïve groups (45.8% vs. 40.3%, p = 0.64).Conclusions: Taxanes following PD-1 blockade in advanced ESCC showed a higher ORR but similar PFS compared to taxanes without prior PD-1 exposure.","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Esophagus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10388-024-01085-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Programmed cell death-1 (PD-1) blockade improves survival in patients with advanced esophageal squamous cell carcinoma (ESCC). However, the efficacy of taxanes after exposure to PD-1 blockade remains unclear in patients with advanced ESCC.

Methods: We retrospectively analyzed the clinical outcomes of advanced ESCC patients treated with taxanes (paclitaxel or docetaxel) with/without prior exposure to PD-1 blockade (Exposed /Naïve group) at National Cancer Center Hospital from June 2016 to December 2020.

Results: Ninety-nine patients (Exposed group, n = 32; Naïve group, n = 67) were included. The objective response rate (ORR) of the Exposed group was significantly higher than that of the Naïve group (37.5% vs. 13.4%, p = 0.009). The median progression-free survival was similar between the Exposed and Naïve groups (3.8 vs. 2.8 months, HR 1.12, 95% CI 0.65-1.86, p = 0.66). PD-1 blockade exposure independently predicated higher ORR to taxanes in multivariate analysis. Grade ≥ 3 adverse events were comparable between the Exposed and Naïve groups (45.8% vs. 40.3%, p = 0.64).

Conclusions: Taxanes following PD-1 blockade in advanced ESCC showed a higher ORR but similar PFS compared to taxanes without prior PD-1 exposure.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

晚期食管鳞状细胞癌接触 PD-1 阻断剂后使用紫杉类药物的影响

背景：程序性细胞死亡-1（PD-1）阻断可提高晚期食管鳞状细胞癌（ESCC）患者的生存率。然而，晚期ESCC患者在接受PD-1阻断治疗后使用紫杉类药物的疗效仍不明确：我们回顾性分析了2016年6月至2020年12月期间国立癌症中心医院接受紫杉类药物（紫杉醇或多西他赛）治疗的晚期ESCC患者的临床结果，这些患者之前接受过/未接受过PD-1阻断剂治疗（暴露组/新药组）：共纳入99名患者（暴露组，n = 32；新药组，n = 67）。暴露组的客观反应率（ORR）明显高于新药组（37.5% vs. 13.4%，P = 0.009）。暴露组和新药组的中位无进展生存期相似（3.8 个月 vs. 2.8 个月，HR 1.12，95% CI 0.65-1.86，p = 0.66）。在多变量分析中，PD-1阻断剂暴露可独立预测更高的紫杉类药物ORR。暴露组和新药组发生≥3级不良事件的比例相当（45.8% vs. 40.3%，p = 0.64）：结论：在晚期ESCC中使用PD-1阻断后的紫杉类药物与未暴露PD-1的紫杉类药物相比，ORR更高，但PFS相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Esophagus GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

4.90

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Esophagus, the official journal of the Japan Esophageal Society, introduces practitioners and researchers to significant studies in the fields of benign and malignant diseases of the esophagus. The journal welcomes original articles, review articles, and short articles including technical notes ( How I do it ), which will be peer-reviewed by the editorial board. Letters to the editor are also welcome. Special articles on esophageal diseases will be provided by the editorial board, and proceedings of symposia and workshops will be included in special issues for the Annual Congress of the Society.